The facilities producing these peptides may not follow any standardized manufacturing protocols, and many of them operate outside the United States entirely, placing them beyond the reach of the FDA
CagriSema FDA approval timeline Novo Nordisk submitted the New Drug Application (NDA) to the FDA on December 18, 2025 , for chronic weight management in adults with obesity or overweight with a weight-related comorbidity
Supports Safe Medication Reconstitution Designed for use as a sterile diluent, bacteriostatic water is commonly used to reconstitute, dissolve, or dilute compatible powdered and concentrated medications prior to administration
Older Adults: Age-related changes, like decreased stomach acid, hinder B12 absorption from food
Vegetarians or vegans with potential B-12 deficiencies